Inmed pharmaceuticals strengthens its commercial leadership team with the appointment of vice president of sales and marketing for baymedica

Vancouver, british columbia, feb. 15, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of gerard (jerry) p. griffin iii as vice president of sales and marketing at baymedica, a wholly owned subsidiary of inmed. mr. griffin will oversee the commercialization of baymedica's health and wellness business including the existing products and the launch of new rare cannabinoid products.
INM Ratings Summary
INM Quant Ranking